Ambalal Sarabhai Enterprises Limited

Ambalal Sarabhai Enterprises Limited (AMBALALSA) is a micro-cap Healthcare company valued at ₹292 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Ambalal Sarabhai Enterprises Limited last traded at ₹37.75, modestly down 0.26% on the day.

Recent developments

On 2026-06-30, the company reported a net profit of ₹0 crore for the latest quarter, a stark contrast to ₹7 crore in the same period last year. This reflects a severe contraction in profitability. Additionally, the company's net profit margin surged 75.0 percentage points to 278.9%, indicating a shift in cost structure or pricing power.

Financial performance

The company's annual revenue fell 2.5% to ₹4 crore, while annual net profit rose 33.4% to ₹11 crore. However, the latest quarter saw a sharp decline, with revenue dropping 67.1% to ₹1 crore and net profit falling 99.6% to ₹0 crore, marking a significant setback compared to the same quarter a year earlier.

Valuation multiples

The stock trades at 26.4 times earnings, a discount to the Healthcare median of 32.0, 1.54 times book value.

Things to watch

The company's latest quarter net profit fell 99.6% to ₹0 crore, signaling a major operational or financial challenge. The net profit margin, though high, is not sustainable if profitability cannot be restored. The company has also not paid dividends despite reporting profits, which may raise concerns about capital allocation and shareholder returns.

Where it stands

The company stands at a critical juncture, with annual net profit rising 33.4% to ₹11 crore, but the latest quarter saw a complete collapse in profitability. The most significant movement is the latest quarter net profit falling to ₹0 crore, highlighting the need for immediate operational clarity and financial stability.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.